All In Biotech

Drug Trial Radar · NCT07857473

A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants

A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study to Investigate the Safety and Efficacy of TE-8105 Administered Subcutaneously in Participants With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Immunwork, Inc.Industry
Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of TE-8105 in adults with overweight or obesity, with or without weight-related health conditions. Participants in this study will receive subcutaneous (under the skin) injections of either TE-8105 or placebo for 25 weeks. The total study duration, including screening and follow-up visits, is approximately 8 months.

Conditions

  • Overweight and Obesity

Interventions

  • TE-8105 MAD Cohort 1Drug

    Administered via SC injection.

  • TE-8105 MAD Cohort 2Drug

    Administered via SC injection.

  • TE-8105 MAD Cohort 3Drug

    Administered via SC injection.

  • PlaceboDrug

    Administered via SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events, including treatment-related adverse events.Time frame: up to 31 weeks after 1st dosing
  2. Changes from baseline in clinical laboratory assessments, physical examination findings, vital signs, and electrocardiogram (ECG) values.Time frame: up to 31 weeks after 1st dosing

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Canopy Clinical Inner West

    Leichhardt, New South Wales, Australia

  • Canopy Clinical Western Sydney

    Penrith, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.